1. Home
  2. SYRE
  3. SYRE News

Latest Spyre Therapeutics Inc. (SYRE) News on August 23, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
SYRE

PR Newswire

2 months ago

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025
SYRE

PR Newswire

2 months ago

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

Spyre Therapeutics Announces Grants of Inducement Awards
SYRE

PR Newswire

3 months ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics to Participate in Upcoming June Investor Conferences
SYRE

PR Newswire

3 months ago

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
SYRE

PR Newswire

3 months ago

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001
SYRE

PR Newswire

4 months ago

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

Spyre Therapeutics Announces Grants of Inducement Awards
SYRE

PR Newswire

4 months ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces Grants of Inducement Awards
SYRE

PR Newswire

5 months ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
SYRE

PR Newswire

5 months ago

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Spyre Therapeutics Announces Grants of Inducement Awards
SYRE

PR Newswire

6 months ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics to Participate in Upcoming March Investor Conferences
SYRE

PR Newswire

6 months ago

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
SYRE

PR Newswire

6 months ago

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Spyre Therapeutics Announces Grants of Inducement Awards
SYRE

PR Newswire

6 months ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts
SYRE

PR Newswire

7 months ago

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Spyre Therapeutics Announces Grants of Inducement Awards
SYRE

PR Newswire

8 months ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Added to the Nasdaq Biotechnology Index
SYRE

PR Newswire

8 months ago

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Spyre Therapeutics Announces Grants of Inducement Awards
SYRE

PR Newswire

9 months ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
SYRE

PR Newswire

9 months ago

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
SYRE

PR Newswire

9 months ago

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
SYRE

PR Newswire

9 months ago

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
SYRE

PR Newswire

9 months ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing
SYRE

PR Newswire

9 months ago

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024
SYRE

PR Newswire

9 months ago

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SYRE

PR Newswire

9 months ago

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Grants of Inducement Awards
SYRE

PR Newswire

10 months ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics to Participate in Upcoming November Investor Conferences
SYRE

PR Newswire

10 months ago

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations
SYRE

PR Newswire

10 months ago

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations

Spyre Therapeutics Announces Grants of Inducement Awards
SYRE

PR Newswire

a year ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer
SYRE

PR Newswire

a year ago

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

Spyre Therapeutics to Participate in Upcoming Investor Conference
SYRE

PR Newswire

a year ago

Spyre Therapeutics to Participate in Upcoming Investor Conference

Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
SYRE

PR Newswire

a year ago

Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
SYRE

GlobeNewswire

a year ago

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease
SYRE

PR Newswire

a year ago

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease

Spyre Therapeutics Announces Grants of Inducement Awards
SYRE

PR Newswire

a year ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
SYRE

PR Newswire

a year ago

Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference

Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors
SYRE

PR Newswire

a year ago

Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors

Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
SYRE

PR Newswire

a year ago

Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Grants of Inducement Awards
SYRE

PR Newswire

a year ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces Grants of Inducement Awards
SYRE

PR Newswire

a year ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces $180 Million Private Placement
SYRE

PR Newswire

a year ago

Spyre Therapeutics Announces $180 Million Private Placement

Spyre Therapeutics Announces Grants of Inducement Awards
SYRE

PR Newswire

a year ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
SYRE

PR Newswire

a year ago

Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
SYRE

PR Newswire

a year ago

Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference

Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
SYRE

PR Newswire

2 years ago

Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation

Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
SYRE

PR Newswire

2 years ago

Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors

Spyre Therapeutics Announces Grants of Inducement Awards
SYRE

PR Newswire

2 years ago

Spyre Therapeutics Announces Grants of Inducement Awards

Safehold Sets Fourth Quarter and Fiscal Year 2023 Earnings Release and Webcast
SYRE

PR Newswire

2 years ago

Safehold Sets Fourth Quarter and Fiscal Year 2023 Earnings Release and Webcast

Docebo to Host Fourth Quarter Fiscal 2023 Conference Call
SYRE

Business Wire

2 years ago

Docebo to Host Fourth Quarter Fiscal 2023 Conference Call

Starbucks (SBUX) Reports Q1: Everything You Need To Know Ahead Of Earnings
SYRE

StockStory

2 years ago

Starbucks (SBUX) Reports Q1: Everything You Need To Know Ahead Of Earnings

5 Stocks to Watch on Their Recent Dividend Hikes
SYRE

Zacks

2 years ago

5 Stocks to Watch on Their Recent Dividend Hikes

PacBio to Report Fourth Quarter 2023 Financial Results on February 15, 2024
SYRE

PR Newswire

2 years ago

PacBio to Report Fourth Quarter 2023 Financial Results on February 15, 2024

Oxford Industries, Inc. (NYSE:OXM) Shares Could Be 26% Below Their Intrinsic Value Estimate
SYRE

Simply Wall St.

2 years ago

Oxford Industries, Inc. (NYSE:OXM) Shares Could Be 26% Below Their Intrinsic Value Estimate

Suburban Propane Partners, L.P. Declares Quarterly Distribution of $0.325 per Common Unit
SYRE

PR Newswire

2 years ago

Suburban Propane Partners, L.P. Declares Quarterly Distribution of $0.325 per Common Unit

City Holding Co Reports Record Annual Earnings for 2023
SYRE

GuruFocus.com

2 years ago

City Holding Co Reports Record Annual Earnings for 2023

City Holding (CHCO) Reports Q4 Earnings: What Key Metrics Have to Say
SYRE

Zacks

2 years ago

City Holding (CHCO) Reports Q4 Earnings: What Key Metrics Have to Say

Open Lending Research Uncovers Near- and Non-Prime Consumers’ Automotive Financing Hopes and Doubts
SYRE

Business Wire

2 years ago

Open Lending Research Uncovers Near- and Non-Prime Consumers’ Automotive Financing Hopes and Doubts

Algoma Steel Provides Update on Incident at Coke-Making Plant
SYRE

GlobeNewswire

2 years ago

Algoma Steel Provides Update on Incident at Coke-Making Plant

7 Speculative Stocks to Double Your Money THIS Year
SYRE

InvestorPlace

2 years ago

7 Speculative Stocks to Double Your Money THIS Year

Bank First (NASDAQ:BFC) Has Announced That It Will Be Increasing Its Dividend To $0.35
SYRE

Simply Wall St.

2 years ago

Bank First (NASDAQ:BFC) Has Announced That It Will Be Increasing Its Dividend To $0.35

indie Semiconductor Sets Date for Fourth Quarter and 2023 Earnings Release and Conference Call
SYRE

Business Wire

2 years ago

indie Semiconductor Sets Date for Fourth Quarter and 2023 Earnings Release and Conference Call

Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
SYRE

Zacks

2 years ago

Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term

ACM Research, Inc. (ACMR) is a Great Momentum Stock: Should You Buy?
SYRE

Zacks

2 years ago

ACM Research, Inc. (ACMR) is a Great Momentum Stock: Should You Buy?

Here's Why You Should Avoid Investing in Berry Global (BERY)
SYRE

Zacks

2 years ago

Here's Why You Should Avoid Investing in Berry Global (BERY)

Lakeland Financial (NASDAQ:LKFN) Is Paying Out A Larger Dividend Than Last Year
SYRE

Simply Wall St.

2 years ago

Lakeland Financial (NASDAQ:LKFN) Is Paying Out A Larger Dividend Than Last Year

Investors might be losing patience for CleanSpark's (NASDAQ:CLSK) increasing losses, as stock sheds 20% over the past week
SYRE

Simply Wall St.

2 years ago

Investors might be losing patience for CleanSpark's (NASDAQ:CLSK) increasing losses, as stock sheds 20% over the past week

PAR Technology Corporation to Participate at the 26th Annual Needham Growth Conference
SYRE

Business Wire

2 years ago

PAR Technology Corporation to Participate at the 26th Annual Needham Growth Conference

Ivanhoe Electric Provides Update on Activities at its Santa Cruz Copper Project in Arizona
SYRE

ACCESSWIRE

2 years ago

Ivanhoe Electric Provides Update on Activities at its Santa Cruz Copper Project in Arizona

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
SYRE

GlobeNewswire

2 years ago

Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders

Ficosa and indie Semiconductor Partner on AI-based Automotive Camera Solutions for Enhanced Safety
SYRE

Business Wire

2 years ago

Ficosa and indie Semiconductor Partner on AI-based Automotive Camera Solutions for Enhanced Safety

Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SYRE

Business Wire

2 years ago

Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference

16 Most Profitable Small-Cap Stocks Now
SYRE

Insider Monkey

2 years ago

16 Most Profitable Small-Cap Stocks Now

Establishment Labs to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SYRE

Business Wire

2 years ago

Establishment Labs to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Does Phreesia (PHR) Have the Potential to Rally 30.09% as Wall Street Analysts Expect?
SYRE

Zacks

2 years ago

Does Phreesia (PHR) Have the Potential to Rally 30.09% as Wall Street Analysts Expect?

This Snack-Food Stock Is Small but Loaded With Upside. Why It’s a Buy.
SYRE

Barrons.com

2 years ago

This Snack-Food Stock Is Small but Loaded With Upside. Why It’s a Buy.

Open Lending Publishes Inaugural ESG Report
SYRE

GlobeNewswire

2 years ago

Open Lending Publishes Inaugural ESG Report

SYRE

Business Wire

2 years ago

AdaptHealth Corp. to Participate in Upcoming Investor Conference

CTS Corporation (NYSE:CTS) Not Flying Under The Radar
SYRE

Simply Wall St.

2 years ago

CTS Corporation (NYSE:CTS) Not Flying Under The Radar

Franklin's (BEN) November AUM Rises 6% on Favorable Markets
SYRE

Zacks

2 years ago

Franklin's (BEN) November AUM Rises 6% on Favorable Markets

Victory Capital (VCTR) November AUM Increases 7.2% to $159.6B
SYRE

Zacks

2 years ago

Victory Capital (VCTR) November AUM Increases 7.2% to $159.6B

Spyre Therapeutics raises $180 million to advance anti-inflammatory drugs
SYRE

BioPharma Dive

2 years ago

Spyre Therapeutics raises $180 million to advance anti-inflammatory drugs

Spyre Therapeutics Announces $180 Million Private Placement
SYRE

PR Newswire

2 years ago

Spyre Therapeutics Announces $180 Million Private Placement

15 Most Consumed Vegetables in the US
SYRE

Insider Monkey

2 years ago

15 Most Consumed Vegetables in the US

Payoneer to Participate in a Virtual Fireside Chat with William Blair on December 12, 2023
SYRE

Business Wire

2 years ago

Payoneer to Participate in a Virtual Fireside Chat with William Blair on December 12, 2023

Kennedy-Wilson Holdings (NYSE:KW) Is Paying Out A Dividend Of $0.24
SYRE

Simply Wall St.

2 years ago

Kennedy-Wilson Holdings (NYSE:KW) Is Paying Out A Dividend Of $0.24

NovaGold Resources Inc. (TSE:NG) is a favorite amongst institutional investors who own 53%
SYRE

Simply Wall St.

2 years ago

NovaGold Resources Inc. (TSE:NG) is a favorite amongst institutional investors who own 53%

UFP Technologies to Present and Host 1X1 Investor Meetings at the Piper Sandler 35th Annual Healthcare Conference
SYRE

GlobeNewswire

2 years ago

UFP Technologies to Present and Host 1X1 Investor Meetings at the Piper Sandler 35th Annual Healthcare Conference

SYRE

PR Newswire

2 years ago

Borr Drilling Limited - Grant of Restricted Stock Units and Share Options

SYRE

Business Wire

2 years ago

AdaptHealth Corp. to Participate in Upcoming Investor Conferences

AdaptHealth Corp. (NASDAQ:AHCO) Q3 2023 Earnings Call Transcript
SYRE

Insider Monkey

2 years ago

AdaptHealth Corp. (NASDAQ:AHCO) Q3 2023 Earnings Call Transcript

SYRE

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Adapthealth Corp Earnings Call

AdaptHealth Corp (AHCO) Reports 6.3% Increase in Q3 Net Revenue Despite Net Loss
SYRE

GuruFocus.com

2 years ago

AdaptHealth Corp (AHCO) Reports 6.3% Increase in Q3 Net Revenue Despite Net Loss

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November
SYRE

GlobeNewswire

2 years ago

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November

SYRE

Business Wire

2 years ago

AdaptHealth Corp. Announces Third Quarter 2023 Results

Ero Copper Corp. (NYSE:ERO) Q3 2023 Earnings Call Transcript
SYRE

Insider Monkey

2 years ago

Ero Copper Corp. (NYSE:ERO) Q3 2023 Earnings Call Transcript

SYRE

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Kforce Inc Earnings Call

Share on Social Networks: